As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.

The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

The model, more common with high-cost gene therapies, is designed to de-risk use of the drug for hospitals in the event that patients with COVID-19-related ARDS do not survive.

Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.